MVA-BN

BIOLOGICAL4 trials

Sponsors

Bavarian Nordic, National Institute of Allergy and Infectious Diseases (NIAID), Shanghai Institute Of Biological Products

Conditions

Monkeypox (Mpox)SmallpoxVariola Major (Smallpox)

Phase 1

Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects

CompletedNCT00189943

Bavarian NordicSmallpox

Start: 2001-04-30End: 2003-07-31Target: 90Updated: 2005-09-19

Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects

CompletedNCT00565929

National Institute of Allergy and Infectious Diseases (NIAID)Variola Major (Smallpox)

Start: 2008-09-30End: 2012-05-31Updated: 2013-08-02

Phase 2

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Active, not recruitingNCT06549530

Bavarian NordicMonkeypox (Mpox)

Start: 2024-10-21End: 2026-05-07Target: 460Updated: 2025-11-24

Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo

Not yet recruitingNCT07253675

Shanghai Institute Of Biological ProductsMonkeypox (Mpox)

Start: 2025-12-31End: 2027-02-28Target: 180Updated: 2025-11-28

Related Papers

PregInPoxVac maternal protocol: a phase 3 trial evaluating maternal immunogenicity and safety of the MVA-BN vaccine in the Democratic Republic of the Congo.

2026-07-28

Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

2013-03-1259 citations